68 results
Page 4 of 4
424B5
zuvgzw td11bt120a
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
nfkym61d2n6 s3scdo
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
2qc2ura57 2ei1ji
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
fzcsfgckhlheddtuf
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
EX-99.2
wxhrsem47tjkkn vhg
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.1
x4xla 39e8tgoyj
13 Jul 18
Ovid Therapeutics Announces Initiation of Phase 2 ROCKET Clinical Trial to Evaluate OV101 in Fragile X Syndrome
9:22pm
S-3
wjw8e94khy6kilh0jxm
1 Jun 18
Shelf registration
5:14pm
10-K
k6t8ktv jgaz9z93li
29 Mar 18
Annual report
12:00am